Work

Abstract CT206: Larotrectinib (L) in patients (pts) with solid tumors with NTRK1/2/3 amplification (amp): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Year: 2026

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2026-ct206

Authors: Jordi Rodon, Michael Rothe, Elizabeth Garrett-Mayer, Nithin Rohatgi, Alvaro G. Menendez, Leighton A. Elliott, Andrew Gregory, Abigail Gregory, Dominique C. Hinshaw, Gina N. Grantham, Susan Halabi, Richard L. Schilsky

Institutions: The University of Texas MD Anderson Cancer Center, American Society of Clinical Oncology, University of Florida Health, UF Health Cancer Center, Aurora Health Care, Duke University, Duke Medical Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7154722085

Cites:

Cited by:

Related to: